Gejun Zhang

155 Nanjing North Road
Shenyang, 110001, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Membrane-derived biomimetic nanovesicles in anti-tumor immunotherapy: Advances and outlook.

Membrane-derived biomimetic nanovesicles in anti-tumor immunotherapy: Advances and outlook.

Journal: Acta pharmaceutica Sinica. B

Published: August 06, 2025

Case Report: Two cases of chemotherapy refractory aggressive variant prostate cancer with extreme durable response to PARP inhibitor.

Case Report: Two cases of chemotherapy refractory aggressive variant prostate cancer with extreme durable response to PARP inhibitor.

Journal: Frontiers in oncology

Published: November 24, 2024

An online clustering algorithm predicting model for prostate cancer based on PHI-related variables and PI-RADS in different PSA populations.

An online clustering algorithm predicting model for prostate cancer based on PHI-related variables and PI-RADS in different PSA populations.

Journal: Cancer cell international

Published: September 26, 2024

Development and validation of a prognostic model based on m6A-related lncRNAs to predict prognosis for papillary renal cell cancer patients.

Development and validation of a prognostic model based on m6A-related lncRNAs to predict prognosis for papillary renal cell cancer patients.

Journal: Scientific reports

Published: July 18, 2024

Development and validation of the utLIFE-PC algorithm for noninvasive detection of prostate cancer in urine: A prospective, observational study.

Development and validation of the utLIFE-PC algorithm for noninvasive detection of prostate cancer in urine: A prospective, observational study.

Journal: Cell reports. Medicine

Published: November 03, 2023

Luteinizing hormone-releasing hormone agonists versus orchiectomy in the treatment of prostate cancer: A systematic review.

Luteinizing hormone-releasing hormone agonists versus orchiectomy in the treatment of prostate cancer: A systematic review.

Journal: Frontiers in endocrinology

Published: December 26, 2022

The efficacy and adverse events of conventional and second-generation androgen receptor inhibitors for castration-resistant prostate cancer: A network meta-analysis.

The efficacy and adverse events of conventional and second-generation androgen receptor inhibitors for castration-resistant prostate cancer: A network meta-analysis.

Journal: Frontiers in endocrinology

Published: December 24, 2022

Different lymph node dissection ranges during radical prostatectomy for patients with prostate cancer: a systematic review and network meta-analysis.

Different lymph node dissection ranges during radical prostatectomy for patients with prostate cancer: a systematic review and network meta-analysis.

Journal: World journal of surgical oncology

Published: September 13, 2022

A dynamic-static combination model based on radiomics features for prostate cancer using multiparametric MRI.

A dynamic-static combination model based on radiomics features for prostate cancer using multiparametric MRI.

Journal: Physics in medicine and biology

Published: July 25, 2022

Correction to: ERCC6L that is up-regulated in high grade of renal cell carcinoma enhances cell viability in vitro and promotes tumor growth in vivo potentially through modulating MAPK signalling pathway.

Correction to: ERCC6L that is up-regulated in high grade of renal cell carcinoma enhances cell viability in vitro and promotes tumor growth in vivo potentially through modulating MAPK signalling pathway.

Journal: Cancer gene therapy

Published: January 28, 2022

PLEKHO1 knockdown inhibits RCC cell viability in vitro and in vivo, potentially by the Hippo and MAPK/JNK pathways.

PLEKHO1 knockdown inhibits RCC cell viability in vitro and in vivo, potentially by the Hippo and MAPK/JNK pathways.

Journal: International journal of oncology

Published: November 17, 2018

ERCC6L that is up-regulated in high grade of renal cell carcinoma enhances cell viability in vitro and promotes tumor growth in vivo potentially through modulating MAPK signalling pathway.

ERCC6L that is up-regulated in high grade of renal cell carcinoma enhances cell viability in vitro and promotes tumor growth in vivo potentially through modulating MAPK signalling pathway.

Journal: Cancer gene therapy

Published: September 01, 2018

Showing 1-12 of 16

Last Updated: 09/26/2026